BiondVax Pharmaceuticals Ltd

BiondVax Pharmaceuticals is a biopharmaceutical company developing a universal flu vaccine designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic.

The company’s technology utilizes a proprietary combination of conserved and common epitopes from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.

BiondVax holds a worldwide exclusive license granted by Yeda Research and Development Ltd, the commercial arm of the Weizmann Institute, for developing, manufacturing, and commercializing its flu vaccine.

BiondVax plans to obtain regulatory approval for M-001 as a primer to a pandemic or seasonal vaccine, and after accumulating enough safety and efficacy information from real-world data, the product will be tested for approval as a universal stand-alone flu vaccine.